Somatic mutations affect key pathways in lung adenocarcinoma

By Li Ding, Gad Getz, D. Wheeler, Elaine R. Mardis, M. McLellan, Kristian Cibulskis, C. Sougnez, H. Greulich, D. Muzny, M. Morgan and 80 more. Nature, 2008

2,751 citations recorded by the source corpus.

Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers—including NF1, APC, RB1 and ATM—and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/eb2021570b76a0a01da6cc39ac3fc9b046e30a98

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data (2011, methodology): “The Data Portal also hosts data from other large-scale cancer genome projects including The Cancer Genome Atlas (TCGA) (8, 9), Tumor Sequencing Project (TSP)(10) and Johns Hopkins University (11–14).”
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016, background): “Meanwhile, mutations in tumor suppressor genes TP53 and STK11 are also common in lung 96 adenocarcinoma and frequently co-occur with KRAS mutations(13-15).”
iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, background): “Mutations resulting from DNA adducts can cause loss of normal cellular growth control functions, via a complex process of signal transduction pathways, ultimately resulting in genomic instability, cellular proliferation and cancer (Ding et al., 2008).”
WebPARE: web-computing for inferring genetic or transcriptional interactions (2009, neutral): “Availability: A web-computing service WebPARE is publicly available at: http://www.stat.sinica.edu.tw/WebPARE Contact: gshieh@stat.sinica.edu.tw Supplementary information: Supplementary data are available at Bioinformatics online.”
Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma (2020, background): “Connecting Driver Mutations to Proteome, Phosphoproteome, and Pathways We examined how selected mutated genes that were significant in prior large-scale LUAD genomics studies (Cancer Genome Atlas Research Network, 2014; Ding et al., 2008) (Table S5) influenced expression of either the cognate gene p”
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). (2015, background): “USA 2 [7, 157] 175/923 19 8-20 459/1656 28 21-28”
A human functional protein interaction network and its application to cancer data analysis (2010, background): “For example, several recent papers [10-14] describe genome-wide screening efforts to identify somatic mutations in several cancer types.”
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (2009, neutral): “Large-scale sequencing of multiple cancers has so far failed to identify new, high-frequency mutation targets in addition to those previously identified (Cancer Genome Atlas Research Network, 2008; Ding et al., 2008; Jones et al., 2008; Parsons et al., 2008; Sjoblom et al., 2006; Wood et al., 2007).”
Integrated Genomic Analyses of Ovarian Carcinoma (2011, background): “Lawrence(3), Nikolaus Schultz(9), Adam Olshen(15), Barbara A.”
The JAK/STAT signaling pathway: from bench to clinic (2021, result): “JAK3 mutation has been reported in many other cancers, such as breast, stomach, and lung cancer.(219,235) Concordant with these results, the samples from patients with NKTCL tumor were found to express JAK3 mutations.”
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening (2011, neutral): “erogeneous disease.(1,2) Advances in surgical, radiotherapeutic, and chemotherapeutic approaches have been made, but the long-term survival rate remains low.”